MS (n = 16) NMOSD (n = 16) ONDs (n = 15)
Men:women 4:12 2:14 9:6
Age, y 36.5 (18–51) 61.0 (27–86) 61.4 (42–75)
Disease duration, y 4.9 (0–20) 5.8 (0–40) -
EDSS 6.0 (1.0–9.0) 6.3 (1.5–9.0) -
Positive AQP4 antibody 0/16 (0%) 16/16 (100%) -
Positive OCB 10/14 (71%) 2/14 (14%) -
CSF cells, /mm3 3.5 (0–43) 4.7 (1–64) 0.7 (0–3)
CSF TP, mg/dL 32 (19–50) 51 (17–160) 37 (18–71)
Qalb, ×10−2 4.9 (2.7–11.7) 6.0 (2.8–37.0) 4.0 (2.7–6.2)
Immunomodulating therapy 4/16 (25%) 5/16 (31%) 0/15 (0%)